Nsclc 2nd line

Second Line Treatment of metastatic Non-Small Cell

Lung Cancer

Update from the World Conference on Lung Cancer

G. Nsouli MD

Tuesday, August 9, 2011

Weekly vs 3-weekly Docetaxel

Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With OnceEvery Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer Di Maio J.Clin. Oncol.2007;25:1377-82

Overall survival (OAS) curves by treatment arm.

Treatment effect on survival within major patient subgroups. PS,performance status.

Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With OnceEvery Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer Di Maio J.Clin. Oncol.2007;25:1377-82

Weekly vs 3-weekly Docetaxel

Pemetrexed vs. Docetaxel in second line

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97

Survival and Toxicity

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97

Elderly Patients Benefit From Second-Line CytotoxicChemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel inPatients With Previously Treated Advanced Non–Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11

Median time to progression (A) for patients younger than 70 years of age:pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months vdocetaxel, 2.9 months (HR, 0.72;

Elderly Patients Benefit From Second-Line CytotoxicChemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel inPatients With Previously Treated Advanced Non–Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11

Median overall survival time (A) for patients younger than 70 years of age:pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86;

Current Guidelines in Second line treatment of NSCLC

• For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival.

• When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.

Nsclc 2nd line

Health & Medicine

Translational research in NSCLC -the role of ETOP and ESMO · ETOP | Name Project | Title Presentation | Zurich, July 27, 2009 First line Second line 3rd linetrial First line 2nd

Immune therapy in NSCLC

Update Nsclc

Mlm nsclc prevencion_oportuno_2016_b

ESMO guidelines in advanced NSCLC 2016 · KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapy as first-Line therapy for advanced NSCLC with a PD-L1 TPS ≥50% Martin Reck, 1

Current standard of care of NSCLC · First TKI versus chemotherapy in EGFR mutated NSCLC. Mok, NEJM 2009. Rosell, Lancet Oncol 2012. First-line TKI therapy in EGFR-mutated NSCLC:

Locally Advanced Nsclc

Building 2nd line leadership ppt

2nd Line - Tom Lichtenheld

5 조 NSCLC

Molecular Biology and Pathology: rivals or companions€¦ · Storyboard 7 20051 20122 2017 80% 60% 40% 20% 9% 0% RESPONSE TO THERAPY NSCLC 2nd Line st No biomarkers OS < 7 mo

NSCLC dengan bronkoskopi

2nd international business forum tuna pole and line hand line kelvin ng

Presentation heading here 2nd line if needed

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

First-line afatinib vs gefitinib for patients with EGFR ... · ORIGINAL ARTICLE - CLINICAL ONCOLOGY First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC

Type ‘Presentation title’ text here 2nd line Type your sub-title here 2nd line Type your ‘Department or School’ 2nd line type date

Immunotherapy vs. Chemoimmunotherapy In First Line · Javelin Avelumab MerckKGA Keynote Pembroluzimab Merck. NSCLC: First Line Randomized Trials ... KN024 Reck (NEJM) 2016, 2019 PD-L1

Maintenance Treatment for Advanced NSCLC · What is Maintenance Therapy? • Patients receive 1 st line treatment for NSCLC (platinum doublet chemotherapy) • Approximately 40% will

NSCLC overview - OverGroupEGFR-TKIs I line treatment of EGFR mutated NSCLC patients STUDIO TERAPIA PZ 0RR (%) PFS (m)IPASS Gefitinib vs CBDCA+Tax 261 71.2 vs 47.3 9.8 vs 6.4 First-Signal